胸苷酸合成酶：接受 5-FU 治疗的结直肠癌肝转移切除术后的预测性生物标志物。

Thymidylate synthase: a predictive biomarker in resected colorectal liver metastases receiving 5-FU treatment.

机构信息

Department of Clinical Sciences, Lund University, Skane University Hospital, SE-221 85 Lund, Sweden.

出版信息

Future Oncol. 2018 Feb;14(4):343-351. doi: 10.2217/fon-2017-0431. Epub 2018 Jan 10.

DOI:10.2217/fon-2017-0431

PMID:29318904

Abstract

AIM

To investigate the role of thymidylate synthase (TS) as a predictive biomarker in patients with resected colorectal liver metastases (CRLM).

MATERIALS & METHODS: PubMed, EMBASE and Cochrane Library were queried up to June 2017. Meta-analysis was performed using random-effects model. Risk of bias was assessed using funnel plots.

RESULTS

Six eligible studies were included, comprising a total of 542 patients. Meta-analysis demonstrated a trend to reduced overall survival in patients with resected CRLM with TS overexpression, with a hazard ratio of 1.13 (95% CI: 0.99-1.29; p = 0.08). In three studies where patients received systemic fluorouracil, the pooled hazard ratio was 2.25 (95% CI: 1.37-3.71; p = 0.001).

CONCLUSION

TS appears to be a clinically relevant predictive biomarker in patients with resected CRLM receiving systemic 5-FU.

摘要

目的

探讨胸苷酸合成酶（TS）作为预测生物标志物在结直肠癌肝转移（CRLM）患者中的作用。

材料与方法

检索 PubMed、EMBASE 和 Cochrane Library 截至 2017 年 6 月的数据。使用随机效应模型进行荟萃分析。使用漏斗图评估偏倚风险。

结果

纳入 6 项符合条件的研究，共纳入 542 例患者。荟萃分析显示，TS 过表达的 CRLM 患者总生存率有降低的趋势，风险比为 1.13（95% CI：0.99-1.29；p=0.08）。在 3 项接受系统氟尿嘧啶治疗的研究中，汇总风险比为 2.25（95% CI：1.37-3.71；p=0.001）。